BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2241187)

  • 1. [Effects of urinastatin against nephrotoxicity of cisplatinum].
    Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
    Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
    Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
    Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
    Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of urinastatin on prevention of cisplatin induced nephrotoxicity].
    Sasa H; Hisano A; Kudo K; Kuki E; Miyauchi M; Kita T; Kikuchi Y; Tode T; Furuya K; Nagata I
    Gan To Kagaku Ryoho; 1991 Dec; 18(15):2623-5. PubMed ID: 1746976
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
    Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
    Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
    Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
    Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
    Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
    Umeki S; Tsukiyama K; Okimoto N; Soejima R
    Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylactic effect of ulinastatin on cisplatin-induced renal disorders in lung cancer patients].
    Horiguchi T; Kasahara J; Ogura K; Handa M; Hosoda H; Shakato A; Tachikawa S; Sato M; Suetsugu S; Umeda H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jan; 30(1):12-9. PubMed ID: 1625386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preventive effect of urinastatin on cisplatin induced nephrotoxicity in rabbits].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):328-32. PubMed ID: 2567322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
    Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinical phase III trial of MR-20 in gynecologic nephrotoxicity of cisplatin--a comparative study in MR-20-treated and control patients on cyclical intermittent cisplatin treatment].
    Ochiai K; Ikeda M; Kobayashi H; Nishimura H; Shibasaki T; Sakai O; Oh-hashi Y; Terashima Y
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):713-22. PubMed ID: 9571969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):888-96. PubMed ID: 4040542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of bismuth subnitrate on cisplatin toxicity].
    Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of side effects of a combination chemotherapy of cisplatin and adriamycin in gynecological malignancies: comparison between intravenous and intraarterial administration].
    Kawagoe K; Tsunoda H; Iijima S; Yokota H; Shigemitsu S
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):452-7. PubMed ID: 6538404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
    Saito M; Masaki T; Kato H; Numasaka K
    Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
    Yogi S; Ikeuchi T; Kai Y
    Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
    Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
    Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.